ERVW-1 and HIV-1 infection: In the RV144 vaccine trial (29, 92), the serum Env-specific IgA level was correlated with an increased risk of HIV-1 infection, which was potentially due to monomeric circulating IgA competing with IgG and interfering with the ability of IgG to mediate ADCC and ADCP (28).